Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers

Powrózek, Tomasz; Krawczyk, Paweł; Kowalski, Dariusz M.; Winiarczyk, Kinga; Olszyna-Serementa, Marta; Milanowski, Janusz

doi:10.1016/j.trsl.2015.05.009

Cited by 56 publications

(49 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be due to the breakdown of the miRNA in the plasma samples. However, the majority of the previous studies in NSCLC did not examine the exosomal miRNAs separated from the plasma or serum, which would likely include the intact miRNA (7)(8)(9)(10)(11)(12)(13)(26)(27)(28)(29). In the present study, microarray-based expression profiling of miRNAs derived from exosomes in the plasma of 6 NSCLC patients with or without recurrence was employed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. Predictive biomarkers for the recurrence of non-small cell lung cancer (NSCLC) in patients who have received curative resection are important for cancer treatment. The functional microRNAs (miRNAs/miRs) in the exosomes of plasma and serum samples are of interest as stable and non-invasive biomarkers for recurrence in cancer patients. The aim of the present study was to clarify the usefulness of plasma exosomal miRNAs as biomarkers for the prediction of recurrence in NSCLC following curative resection. First, microarray-based expression profiling of miRNAs derived from exosomes in the plasma of 6 patients was employed to identify a biomarker that distinguishes between patients with and without NSCLC recurrence. In the miRNA microarray analyses, the exosomal miR-21 and miR-4257 levels of the NSCLC patients showed marked upregulation in those individuals with recurrence compared with those without recurrence and healthy individuals. These two miRNAs were thus selected as recurrence-specific biomarkers and their potential was evaluated in a separate cohort of 195 NSCLC patients. In comparison to the levels in 30 healthy individuals, exosomal miR-21 and miR-4257 levels showed a significant increase in the NSCLC patients (P<0.01). When evaluating the clinicopathological significance of these miRNAs, exosomal miR-21 showed a significant association with tumor size and tumor-node-metastasis (TNM) stage (P<0.05). Exosomal miR-4257 showed a significant association with histological type, lymphatic invasion and TNM stage (P<0.05). The disease-free survival (DFS) rates of high exosomal miR-21 patients were significantly worse than those of low exosomal miR-21 patients (P<0.05), and the DFS rates of patients with high exosomal miR-4257 levels were significantly worse than those with low exosomal miR-4257 levels (P<0.01). In the Cox multivariate analysis, plasma exosomal miR-21 and miR-4257 expression showed a significance association with DFS (P<0.05). These results suggest that plasma exosomal miR-21 and mir-4257 expression has potential as a predictive biomarker for recurrence in NSCLC patients who have received curative resection. IntroductionLung cancer, mainly non-small cell lung cancer (NSCLC), is the leading cause of cancer-associated mortality globally. More than 133,000 new diagnoses and over 77,000 associated mortalities are expected to occur in 2015 in Japan (1). In spite of progress in NSCLC therapy, the prognosis for patients with NSCLC remains poor (2). Therefore, clarification of the biomarkers most likely to predict the recurrence of NSCLC after curative surgery is required to improve the outcome of NSCLC patients.MicroRNAs (miRNAs/miRs) are one of the most compelling molecular markers in the diagnosis and prognosis of tumors (3,4). miRNAs are short (20-24 nt) non-coding RNAs that take part in the post-transcriptional regulation of gene expression in multicellular organisms by impacting mRNA stability and translation. miRNAs target protein-coding mRNAs at the post-transcriptional level by directly c...

show abstract

Section: Discussionmentioning

confidence: 99%

“…In NSCLC, certain studies have shown the prognostic value of specific miRNAs in the plasma and serum (8)(9)(10)(11). Furthermore, a focus has been placed on miRNAs that have also been identified in the exosome of plasma and serum in an unexpectedly stable form, which is protected from endogenous RNase activity (12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…And the expression of miRNA-944 may correlate with TP63 expression [17]. miRNA-944, which targets an mRNA of SOCS (suppressor of cytokine signaling) family tumor suppressor genes, can promote tumor growth, proliferation, and squamous differentiation [18].…”

Section: Discussionmentioning

confidence: 99%

Expressions and clinic significance of miRNA-143, miRNA- 34A, miRNA-944, miRNA-101 and miRNA-218 in cervical cancer tissues

Wang¹,

Zhang²,

Fu³

et al. 2016

Trop. J. Pharm Res

View full text Add to dashboard Cite

75 and 0.73 (n = 10), 382 and 2.72 (n = 25), 912.9 and 3.93 (n = 21), 1675 and 5.87 (n = 29), and 2120 and 6.66 (n = 11), respectively. Furthermore, qRT-PCR results showed that the expressions of miRNA-944 and miRNA-218 in cervical cancer tissues were markedly up-regulated compared to normal control tissues (p < 0.01). In contrast, the expression level of . Conclusion: The biomarkers, can be considered novel for early diagnosis of cervical cancer.

show abstract

“…48 Powrozek et al also identified significant changes in miRNA-944 and miR-NA-3662 expressions in lung cancer. 49 If we were to have a global view on the molecular changes induced by oncological diseases, we can say that for each type of cancer there is -or should be -a specific type of miRNA or a certain miRNA with higher specificity. Clearly, there has been extensive research on specific miRNAs in different types of cancer, more than what we have mentioned so far.…”

Section: Using Mirnas As a Biomarker For Cancermentioning

confidence: 99%

Use of Circulating and Cellular miRNAs Expression in Forensic Sciences

Dumache

Rogobete

Săndesc

et al. 2017

Journal of Interdisciplinary Medicine

View full text Add to dashboard Cite

The current practice in the field of forensic medicine imposes the use of modern investigation techniques. The complexity of laboratory investigation methods needed for a final result of the investigation in forensic medicine needed new biomarkers of higher specificity and selectivity. Such biomarkers are the microRNAs (miRNAs), short, non-coding RNAs composed of 19-24 nucleotides. Their characteristics, such as high stability, selectivity, and specificity for biological fluids, differ from tissue to tissue and for certain pathologies, turning them into the ideal candidate for laboratory techniques used in forensic medicine. In this paper, we wish to highlight the biochemical properties and the usefulness of miRNAs in forensic medicine.

show abstract

Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers

Cited by 56 publications

References 31 publications

Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer

Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer

Expressions and clinic significance of miRNA-143, miRNA- 34A, miRNA-944, miRNA-101 and miRNA-218 in cervical cancer tissues

Use of Circulating and Cellular miRNAs Expression in Forensic Sciences

Contact Info

Product

Resources

About